Itonis Inc (ITNS)

[profiteer11]

Quarterly was filed
https://www.otciq.com/otciq/ajax/showFinancialReportById.pdf?id=119108

Paramount is DONE!
The Company determined that Paramount Discoveries, Inc. was not meeting its
development milestones and decided to stop funding the development of Paramount’s
technologies. As part of this decision, one of the principals of the Paramount returned
28,000,000 shares of common stock that had been issued when the Company acquired
the technologies. The Company concurrently wrote off $640,000 that it had
capitalized when Paramount was acquired. The company also abandoned $30,000 in
inventory costs related to Paramount.

The company has placed a manufacturing order for Emesyl



In August 2012, the Company launched a new Itonis Pharmaceuticals division headed by
Dr. Charles Hensley, Ph.D. to produce and market over the counter and prescription
homeopathic preparations to treat both common ailments and chronic diseases. The
Company has placed a manufacturing order for the first batch of its Emesyl™ product
line.

In March 2014, the Company signed a licensing agreement with MyECheck, Inc. for the
Company to implement a mobile app for point-of-purchase sales transactions in the
medical marijuana, gambling, and general retail sectors.

In April 2014, the Company introduced a new cannabinoid-based project that is code
named the Cloud9 Project, which is in the final testing phase.